Peptide Comparison
GHRP-2 vs Sermorelin
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
GHRP-2 and Sermorelin share the gh-secretagogue class and carry roughly equivalent evidence (Japan-Approved Diagnostic / Discontinued (FDA approval 1990; US withdrawal 2008)). On the catalogued data layer Sermorelin has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Sermorelin's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| GHRP-2 | Sermorelin | |
|---|---|---|
| Class | GHRP; ghrelin receptor agonist | GHRH analog |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | GHS-R1a agonist; strong GH release | Binds GHRH receptor on pituitary somatotrophs for pulsatile GH release |
| Route | SC / Intranasal | SC injection |
| Half-life | ~15-30 min | ~10-20 min |
| Dosage (research) | 100-300 mcg SC 1-3x daily | 200-500 mcg SC at bedtime daily |
| Evidence tier | Japan-Approved Diagnostic | Discontinued (FDA approval 1990; US withdrawal 2008) |
| Research depth | 148 indexed | 149 indexed |
| Availability | Research | Compounding Restricted |
| Reported risks | Cortisol/prolactin increase; hunger; water retention | Injection site reactions; headache; flushing |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick GHRP-2 or Sermorelin?
GHRP-2 and Sermorelin share the gh-secretagogue class and carry roughly equivalent evidence (Japan-Approved Diagnostic / Discontinued (FDA approval 1990; US withdrawal 2008)). On the catalogued data layer Sermorelin has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Sermorelin's evidence base is currently denser.
What is the difference between GHRP-2 and Sermorelin?
GHRP-2 is classed as GHRP; ghrelin receptor agonist; Sermorelin is classed as GHRH analog. Reported mechanism: GHRP-2, GHS-R1a agonist; strong GH release; Sermorelin, Binds GHRH receptor on pituitary somatotrophs for pulsatile GH release. Reported half-life: GHRP-2, ~15-30 min; Sermorelin, ~10-20 min. Routes in published studies: GHRP-2, SC / Intranasal; Sermorelin, SC injection.
Which has stronger evidence, GHRP-2 or Sermorelin?
GHRP-2 and Sermorelin sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. GHRP-2 is graded Japan-Approved Diagnostic, with 1 cited source on its reference page and 148 indexed studies. Sermorelin is graded Discontinued (FDA approval 1990; US withdrawal 2008), with 6 cited sources on its reference page and 149 indexed studies.
Which is more accessible, GHRP-2 or Sermorelin?
Neither GHRP-2 nor Sermorelin is an FDA-approved drug. Catalog status: GHRP-2, Research; Sermorelin, Compounding Restricted. FDA lists GHRP-2 in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023).
Are GHRP-2 and Sermorelin ever combined?
GHRP-2 and Sermorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…